Darbepoetin alfa

Identification

Name
Darbepoetin alfa
Accession Number
DB00012 / 15UQ94PT4P
Groups
Aranesp
Description

Human erythropoietin with 2 aa substitutions to decorate glycosylation (5 N-connected chains), a hundred sixty five residues (MW=37 kD). Produced in chinese hamster ovary (CHO) cells through recombinant DNA technology.

Pharmacology

Pharmacodynamics

Darbepoetin alfa is used in the treatment of anemia. It is involved in the regulation of erythrocyte differentiation and the maintenance of a physiological level of circulating erythrocyte mass.

Indication

For the treatment of anemia (from renal transplants or certain HIV treatment)

Action

Darbepoetin alfa stimulates erythropoiesis by the same mechanism as endogenous erythropoietin. Erythropoietin interacts with progenitor stem cells to increase red cell production. Binding of erythropoietin to the erythropoietin receptor leads to receptor dimerization, which facilitates activation of JAK-STAT signaling pathways within the cytosol. Activated STAT (signal transducers and activators of transcription) proteins are then translocated to the nucleus where they serve as transcription factors which regulate the activation of specific genes involved in cell division or differentiation.